Evaluation of hypoxia-specific cytotoxic bioreductive agent-sodium borocaptate-10B conjugates as10B-carriers in boron neutron capture therapy
Tóm tắt
To evaluate the usefulness of 5 new10B-compounds (TX-2091, TX-2095, TX-2097, TX-2100, and TX-2110) as10B-carriers in boron neutron capture therpy (BNCT). They were conjugates that had been synthesized from a hypoxia-specific cytotoxic bioreductive agent, quinoxaline oxide TX-402 and a clinically used10B-carrier, sodium borocaptate-10B (BSH). The 5 new compounds were hybrid compounds that have both a hypoxic cytotoxin unit and a thermal neutron-sensitizing unit, BSH. These new compounds and BSH were administered intraperitoneally to SCC VII tumor-bearing mice. Then, the10B concentrations in the tumors and normal tissues were measured by γ-ray spectrometry. Subsequently, SCC VII tumor-bearing mice were continuously given 5-bromo-2′-deoxyuridine (BrdU) to label all proliferating (P) cells in the tumors, then treated with TX-2100, which was chosen based on the results of the above-mentioned biodistribution analyses, or BSH in the same manner as in the biodistribution studies. Right after irradiation, during which intratumor10B concentrations were kept at levels similar to each other, the tumors were excised, minced, and trypsinized. The tumor cell suspensions thus obtained were incubated with cytochalasin-B (a cytokinesis blocker), and the micronucleus (MN) frequency in cells without BrdU labeling [=quiescent (Q) cells] was determined using immunofluorescence staining for BrdU. Meanwhile, the MN frequency in the total (P+Q) tumor cell population was determined from the tumors that were not pretreated with BrdU. Clonogenic cell survival was also determined in mice given no BrdU.
10B biodistribution analyses in tumors, brain, skin, muscles, blood, and liver indicated that TX-2100 has the most favorable characteristics for concentrating a sufficient amount of10B in tumors and maintaining a high enough10B concentration during irradiation. In addition, TX-2100 had a significantly stronger radio-sensitizing effect with reactor thermal neutron beams than BSH on both total and Q cells in solid tumors. Further, TX-2100 clearly exhibited a radio-sensitizing effect with γ-rays not only on total cells but also on Q and hypoxic tumor cells, which was not achieved by BSH. A10B-carrier that acts as a hypoxic cytotoxin on tumor cells as well as having the potential to keep10B in tumors and sensitize tumor cells more markedly than conventional10B-carriers, such as TX-2100, is a promising candidate for use in BNCT.
Tài liệu tham khảo
Coderre JA, Morris GM. The radiation biology of boron neutron capture therapy.Radiat Res, 151: 1–18, 1999.
Masunaga S, Ono K. Significance of the response of quiescent cell populations within solid tumors in cancer therapy,J Radiat Res, 43: 11–25, 2002.
Hori H, Jin CZ, Kiyono M, Kasai S, Shimamura M, Inayama S. Design, synthesis, and biological activity of anti-angiogenic hypoxic cell radiosensitizer haloacetylcarbamoyl-2-nitroimidazoles.Bioorg Med Chem, 5: 591–599, 1997.
Kobayashi T, Kanda K. Microanalysis system of ppm-order10B concentrations in tissue for neutron capture therapy by prompt γ-ray spectrometry.Nucl Instrum Methods, 204: 525–531, 1983.
Caswell RS, Coyne JJ, Randolph ML. Kerma factors for neutron energies below 30 MeV.Radiat Res, 83: 217–254, 1980.
Sakurai Y, Kobayashi T. Characteristics of the KUR heavy water neutron irradiation facility as a neutron irradiation field with variable energy spectra.Nucl Instr Meth Phys Res, A453: 569–596, 2000.
Ando K, Koike S, Ohira C,et al. Accelerated reoxygenation of a murine fibrosarcoma after carbon-ion radiation.Int J Radiat Biol, 75: 505–512, 1999.
Masunaga S, Takahashi A, Ohnishi K,et al. Effects of p53 status and wortmannin treatment on potentially lethal damage repair, with emphasis on the response of intra-tumor quiescent cells.Radiat Med, 21: 120–127, 2003.
Maruyama K, Ishida O, Kasaoka S,et al. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT).J Control Release, 98: 195–207, 2004.
Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies.Mol Med Today, 6: 157–162, 2000.
Rofstad EK. Microenvironment-induced cancer metastasis.Int J Radiat Biol, 76: 589–605, 2000.
Brown JM, Wang LH. Tirapazamine: laboratory data relevant to clinical activity.Anticancer Drug Des, 13: 529–539, 1998.
Nagasawa H, Yamashita M, Mikamo N,et al. Design, synthesis and biological activities of antiangiogenic hypoxic cytotoxin, triazine-N-oxide derivatives.Comp Biochem Physiol A Mol Integr Physiol, 132: 33–40, 2002.
Hall EJ. The oxygen effect and reoxygenation. InRadiobiology for the Radiologist, 5th ed. (Hall EJ ed.; Lippincott Williams & Wilkins, Philadelphia), pp. 91–111, 2000.
Masunaga S, Ono K, Sakurai Y,et al. Response of quiescent and total tumor cells in solid tumors to neutrons with various cadmium ratios.Int J Radiat Oncol Biol Phys, 41: 1163–70, 1998.
Masunaga S, Ono K, Akaboshi M,et al. Reduction of hypoxic cells in solid tumours induced by mild hyperthermia: special reference to differences in changes in the hypoxic fraction between total and quiescent cell populations.Br J Cancer, 76: 588–593, 1997.
Masunaga S, Ono K, Sakurai Y,et al. Evaluation of apoptosis and micronucleation induced by reactor neutron beams with two different cadmium ratios in total and quiescent cell populations within solid tumors.Int J Radiat Oncol Biol Phys, 51: 828–839, 2001.
Masunaga S, Nagasawa H, Hiraoka M,et al. Applicability of the 2-nitroimidazole-sodium borocaptate-10B conjugate, TX-2060, as a10B-carrier in boron neutron capture therapy.Anticancer Res, 24: 2975–2983, 2004.
Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.Cancer Res, 58: 1408–1416, 1998.
Vaupel P, Kelleher DK, Hoeckel M. Oxygenation status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy.Semin Oncol, 28 (2 Suppl 8): 29–35, 2001.